|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
GeneticVariation |
BEFREE |
Paternal transmission of DRB1 alleles encoding a +2 charge 3rd HVR was significantly reduced in SSc patients compared with maternal transmission (p = 0.0003, corrected for analysis of four charge categories p = 0.001).
|
28270189 |
2017 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
GeneticVariation |
BEFREE |
Secondary analyses of all DRB1 allele groups revealed an association with DRB1*10 (10.5% of patients with juvenile-onset SSc versus 1.5% of controls; OR 7.48, P = 0.0002).
|
27214100 |
2016 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
Biomarker |
BEFREE |
However, there was a significant association between DRB1*01:01, DRB1*10:01, DQB1*05:01, and DPB1*04:02 and the susceptibility to SSc with ACA.
|
27116456 |
2016 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
GeneticVariation |
BEFREE |
We also confirmed previous associations of HLA-DRB1*11:04 and -DRB1*01 to susceptibility to develop SSc.
|
25993664 |
2015 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
GeneticVariation |
BEFREE |
We further observed a consistent negative association of HLA-DRB1(∗)13 allele with SLE, Ps + PsA, RA, and SSc (18.3%, 19.3%, 16.3%, and 11.9%, resp., versus 29.8% in controls).
|
26605347 |
2015 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
GeneticVariation |
BEFREE |
Polymorphisms in exons 2-4 for HLA-A, -B, -C loci, exon 2 for HLA-DRB1 and exons 2,3 for HLA-DQB1 were analyzed for association with PSS at allele and haplotype levels.
|
26161794 |
2015 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
Biomarker |
BEFREE |
In addition, DRB1*11 and *07∶01 also showed significant association with SSc as a risk for and protection from SSc, respectively, and which is consistent with the studies of Spanish, US Caucasian and Hispanic populations.
|
25184637 |
2014 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
Biomarker |
BEFREE |
Among the HLA-DR*15 alleles, the AF of the DRB1*15:02 was increased significantly in all SSc patients (29.0 vs 12.6%, Pc = 0.0219) and SSc patients with anti-Scl70+ (32.4 vs 12.6%, Pc = 0.0196).
|
23404077 |
2013 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, FLEDR is always carried by the most abundantly expressed ß chain: ß1 in HLA DRB1*11 haplotypes and ß5 in HLA-DRB1*15 haplotypes.In French Caucasian patients with SSc, FLEDR is the main presenting motif influencing ATA production in dcSSc.
|
22615829 |
2012 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
GeneticVariation |
BEFREE |
Fifty (18.5%) AA patients had AFA.After Bonferroni correction, HLA-DRB1*08:04 was associated with AFA, compared to unaffected AA controls (OR 11.5, p < 0.0001) and AFA-negative SSc patients (OR 5.2, p = 0.0002).
|
21572159 |
2011 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
GeneticVariation |
BEFREE |
To determine human leucocyte antigen-class II (HLA-class II) (DRB1, DQB1, DQA1 and DPB1) alleles, haplotypes and shared epitopes associated with scleroderma (systemic sclerosis (SSc)) and its subphenotypes in a large multi-ethnic US cohort by a case-control association study.
|
19596691 |
2010 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
Biomarker |
BEFREE |
His HLA type included both the B27 allele conferring susceptibility to ankylosing spondylitis and the B35, DRB1 11, and DQB1 03 described as associated with systemic sclerosis.
|
19372061 |
2009 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
Biomarker |
BEFREE |
HLA-DRB1*11 was associated with genetic susceptibility to SSc, whereas HLA-DRB1*07 (HLA-DRB1*0701) showed a protective effect.
|
19884273 |
2009 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
Biomarker |
BEFREE |
Complete HLA-DRB1 typing was obtained for 58 SSc and 68 control families (proband/children).
|
19208687 |
2009 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
Biomarker |
BEFREE |
HLA-DRB1*11 and DQB1*03 associated with SSc.
|
17392350 |
2007 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
GeneticVariation |
BEFREE |
The frequency of the HLA-DRB1*03-DQA1*05-DQB1*02 haplotype was significantly increased in the JDM-SSc (P = 0.003) and anti-PM-Scl antibody (P = 0.002) positive groups.
|
18003662 |
2007 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
Biomarker |
BEFREE |
On the other hand, others are more disease specific (HLA-DRB1*11 for systemic sclerosis and HLA-DRB1 alleles encoding the "shared epitope" in RA) as well as non MHC genes, such as FcyRIIa and IIIa in SLE, the beta2 glycoprotein I gene in the aPL syndrome, and the TSHR gene in Graves' disease).
|
16890892 |
2006 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
GeneticVariation |
BEFREE |
The HLA-DRB1*15 allele was associated with the development of anti-topo I-positive SSc in Koreans.
|
16467040 |
2006 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
Biomarker |
BEFREE |
HLA-DRB1*01 and HLA-DRB1*11 were associated with susceptibility to scleroderma, whereas HLA-DRB1*07 was protective.
|
16078323 |
2005 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
Biomarker |
BEFREE |
In contrast, in limited SSc the strongest association was with DRB1*1101 (P = 0.008), with a less significant increase of DRB1*1104 (P = 0.04).
|
15572392 |
2005 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
Biomarker |
BEFREE |
Increased frequencies of DR2 in the overall SSc group (OR = 2.4), DRB1*0301 in the limited cutaneous SSc (lcSSc) subset (OR = 9.0), and DQB1*0301/4 in the diffuse cutaneous SSc (dcSSc) subset (OR = 9.0) were observed.
|
15104683 |
2004 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
GeneticVariation |
BEFREE |
A significant increase in the +49A was not observed in SSc with HLA-DRB1*1502 or ORB1*0802.
|
12508774 |
2003 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
Biomarker |
BEFREE |
HLA-DQB1*0301 was significantly associated with SSc per se in all 3 ethnic groups; HLA-DRB1*11 correlated with the anti-topoisomerase I antibody response, and HLA-DRB1*01, DRB1*04, and DQB1*0501 with ACA.
|
11303306 |
2001 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
GeneticVariation |
BEFREE |
Among anti-topo I negative patients, diffuse and limited subtypes of SSc were significantly associated with DRB1*0803 (47% vs 15% in controls; Pcorr < 0.05) and DRB1*1501 (50% vs 17% in controls; Pcorr < 0.01), respectively.
|
11469465 |
2001 |
|
HLA-DRB1
|
Systemic Scleroderma
|
0.100 |
GeneticVariation |
BEFREE |
HLA-DRB1*1502; DQB1*0601 has been reported to be the most frequent anti-topo I associated haplotype among Japanese SSc patients.
|
11776400 |
2001 |